Ads with unpublicized fatality/serious-damage information require prior FDA approval once FDA so notifies

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

No advertisement for a prescription drug may be disseminated without prior FDA approval if all three conditions are met: (i) the sponsor or FDA has received information, not widely publicized in medical literature, that the drug may cause fatalities or serious damage; (ii) FDA has notified the sponsor that the information must be part of the drug's advertisements; and (iii) the sponsor has failed, within the time specified in that notification, to present to FDA a program adequate to assure that the information will be publicized promptly and adequately to the medical profession in subsequent advertisements. Where a program was presented but FDA finds it is not being followed, prior approval applies only after FDA notifies the sponsor that prior approval of all advertisements for that drug will be required.

Check

Determine whether FDA has notified the sponsor under (j)(1)(ii) that unpublicized fatality/serious-damage information must be included in the drug's advertisements. Confirm whether FDA's notification under (j)(1)(ii) exists AND whether the sponsor responded with a presented program: if a notification exists and the sponsor either failed to present an adequate program within the specified time, or presented one that FDA later found was not being followed and FDA has since required prior approval, the advertisement must have received prior FDA approval before dissemination. The bar does not apply solely because an unpublicized safety signal exists without a (j)(1)(ii) notification.

Escalate when

Requires confirmation of whether FDA issued a (j)(1)(ii) notification for the product, what time period it specified, whether the sponsor presented a program within that time, and whether FDA later found the program was not being followed and re-notified the sponsor — all external regulatory facts requiring escalation/verification.

Where this comes from

21 CFR 202.1(j)(1)(i)-(iii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

… or suggested to be authentic or authoritative. (f)-(i) [Reserved] (j)(1) No advertisement concerning a particular prescription drug may be disseminated without prior approval by the Food and Drug Administration if: (i) The sponsor or the Food and Drug Administration has received information that has not been widely publicized in medical literature that the use of the drug may cause fatalities or serious damage; (ii) The Commissioner (or in his absence the officer acting as Commissioner), after evaluating the reliability of such information, has notified the sponsor that the information must be a part of the advertisements for the drug; and (iii) The sponsor has failed within a reasonable time as specified in such notification to present to the Food and Drug Administration a program, adequate in light of the nature of the information, for assuring that such information will be publicized promptly and adequately to the medical profession in subsequent advertisements. If the Commissioner finds that the program presented is not being followed, he will notify the sponsor that prior approval of all advertisements for the particular drug will be required. Nothing in this paragraph is to be construed as limiting the Commissioner's or the Secretary's rights, as authorized by law, to issue publicity, to suspend any new-drug application, to decertify any antibiotic, or to recommend any …

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The source does establish a prior-approval requirement: (j)(1) is binding regulation text and (j)(3) makes dissemination out of compliance a misbranding act. So the rule is supported in substance.
- But the rule misstates the third trigger condition, making it broader than the source. (j)(1)(iii) requires that 'the sponsor has failed within a reasonable time as specified in such notification to present to the Food and Drug Administration a program' — a failure to SUBMIT a program to FDA. The rule says 'the sponsor has not implemented an adequate program to publicize it,' which would fire on a sponsor that presented an adequate program but executed it poorly.
- The source handles that different situation separately and with an extra step: 'If the Commissioner finds that the program presented is not being followed, he will notify the sponsor that prior approval of all advertisements for the particular drug will be required.' Prior approval there attaches only after that further FDA notification, so the rule's version fires earlier than the regulation does.
- The rule also compresses conditions (i) and (ii) into one clause. That is acceptable as written ('FDA has notified the sponsor that unpublicized information about possible fatalities or serious damage must be included in ads' fairly captures (i)+(ii)), but the notification element from (ii) should be kept explicit so a reviewer does not treat mere awareness of a safety signal as the trigger.
- Atomic: it is one requirement (do not disseminate without prior approval) gated by a conjunctive condition set; conjunctive gating is not bundling.
- determinism 'judgment' is defensible: the trigger turns on external regulatory facts and on whether a submitted program is 'adequate in light of the nature of the information,' neither of which is settled by presence/absence in the piece.
- authority 'binding' is correct; severity 'blocker' is defensible given (j)(3); locator 21 CFR 202.1(j)(1) matches; applies_when 'promotional' is justified since the paragraph governs advertisements.
- The quote is only the chapeau of (j)(1), which by itself does not convey the conditions — acceptable since the locator points to the full paragraph, but the quote should be extended so a reader of the rule can see the gating conditions.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- 21 CFR 202.1(j)(1) states that no advertisement 'may be disseminated without prior approval' where conditions (i), (ii) and (iii) are met; the rule reproduces all three conditions conjunctively rather than converting any one of them into a standalone trigger.
- The rule correctly captures the flush text following (j)(1)(iii): where a program was presented but FDA finds it is not being followed, prior approval attaches only after FDA notifies the sponsor. This is the clause most easily overstated, and it is stated faithfully.
- The check explicitly says the bar does not apply merely because an unpublicized safety signal exists absent a (j)(1)(ii) notification, which guards against exactly the broadening the source does not support.
- 'Judgment' is defensible: nothing in the reviewed piece settles the question, and the determination rests on external regulatory facts (existence and timing of FDA notifications and the sponsor's response) rather than a literal match.
- Authority 'binding' is correct; 'blocker' is defensible since dissemination in violation of (j) is deemed under (j)(3) to cause the drug to be misbranded. The locator (j)(1)(i)-(iii) matches, and the additional 'program not being followed' sentence sits in the undesignated flush text of the same paragraph.